Retail Giants Criticized for Delayed Recall of Contaminated Baby Formula
In a significant oversight, several leading retail chains in the U.S. continued to have potentially hazardous infant formula on their shelves, despite a recall issued following a botulism scare. This delay in action has prompted federal health officials to issue warning letters to the involved companies.
The U.S. Food and Drug Administration (FDA) has reached out to Walmart, Target, Kroger, and Albertsons, highlighting their failure to quickly remove ByHeart infant formula from sale. This recall, initiated on November 11 after reports of botulism affecting over 50 infants across 19 states, was not adhered to by these retailers in a timely manner.
“As a participant in the supply chain, your firm should take prompt and effective action when notified of a product recall,” the FDA emphasized in its communications to these companies on December 12, which were made public on Monday.
The FDA’s findings showed that Target stores in 20 states continued to stock the formula well beyond the recall date. Notably, a store in New Hampshire sold the formula on November 16, notwithstanding an electronic block intended to prevent such sales. Moreover, a Target location in Arkansas promoted the product with a discount from November 16 to November 22.
Additionally, state and local health officials reported the presence of ByHeart formula in Walmart stores across 21 states from November 12 to November 26. Similarly, Albertsons and Kroger stores in several states were also found to have the product available during the same period.
The FDA has also pointed out that these companies have not yet provided evidence of corrective measures, despite multiple requests. They have been given a 15-day window to respond to these warnings.
Walmart’s response claimed, “We moved swiftly to issue a sales restriction and removed this product from our impacted stores and clubs and online.” The company assured that no sales occurred post-recall due to blocked sales codes.
Albertsons also stated that it worked with suppliers and regulators to ensure the removal of the product, confirming, “ByHeart infant formula products have been removed from our store shelves.”
The affected infants have been hospitalized and treated with an IV medication to halt the disease’s progression. The Centers for Disease Control and Prevention has broadened the scope of this outbreak to include all infants treated for botulism after consuming ByHeart formula since its initial production in 2023.
Steven Mandernach, executive director at the Association of Food and Drug Officials, criticized the FDA for its slow dissemination of recall information to state and local officials. He noted that the agency delayed sharing complete product lists until November 14, nearly a week post the initial recall announcement.
Mandernach described the situation as “disappointing,” especially considering the vulnerability of the affected infants. He remarked, “There probably wasn’t the sense of urgency to ensure the product was off the market that I would expect.”
This article was originally written by www.npr.org
